Shionogi
VC Fund
Osaka-shi, Japan
Shionogi is a VC fund in Osaka-shi focused on Biotechnology and Health Care. Shionogi provides pharmaceuticals, diagnostic reagents, and medical devices. They specialize in generic drug manufacturing. They engage in manufacturing, formulation, packaging, and analysis of commercialization research that spans late-stage drug discovery through commercial production.
- Total investments:
- 12
- Last investment:
- Lead investor:
- 33%
Last updated:
For AI agents: llms.txt
Industries Shionogi invests in
Stages Shionogi invests in
Countries Shionogi invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Jimmy Chen
|
|||
Ed Schutter
|
|||
|
Lance Bennett
|
|||
Margaret Borys
|
|||
Suzie Henderson
|
Investment Focus
Industry
- Biotechnology 6 (50%)
- Health Care 5 (42%)
- Medical 4 (33%)
- Therapeutics 3 (25%)
- Medical Device 2 (17%)
Stage
- Series A 3 (25%)
- Corporate Round 3 (25%)
- Funding Round 2 (17%)
- Series B 1 (8%)
- Series C 1 (8%)
Country
- Japan 6 (50%)
- United States 3 (25%)
- France 1 (8%)
- United Kingdom 1 (8%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Jimmy Chen
Senior Director, Pharmaceutical Sciences
|
Senior Director, Pharmaceutical Sciences | Total investments: 0 | Find email | |
|
Ed Schutter
President and Chief Operating Officer
|
President and Chief Operating Officer | Total investments: 1 | Find email | |
|
Lance Bennett
KAM Leader, West Region
|
KAM Leader, West Region | Total investments: 0 | Find email | |
|
Margaret Borys
SVP & Chief Commercial Officer
|
SVP & Chief Commercial Officer | Total investments: 0 | Find email | |
|
Suzie Henderson
Senior Submission Manager, Regulatory Affairs
|
Senior Submission Manager, Regulatory Affairs | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Restore Vision
|
Restore Vision is a biotechnology company developing a visual restoration gene therapy for retinitis pigmentosa. Restore Vision develops eye disease therapeutic agents. | $8.2M / Series B / Apr 15, 2026 | |
ViiV Healthcare
|
ViiV Healthcare is a global specialist HIV company established in November 2009 by GlaxoSmithKline (NYSE: GSK) and Pfizer (NYSE: PFE) dedicated to delivering advances in treatment and care for people living with HIV. Our aim is to take a deeper and broader interest in HIV/AIDS than any company has done before and take a new approach to delivereffective and new HIV medicines as well as support communities affected by HIV. | $2.1B / Corporate Round / Jan 20, 2026 | |
CILcare
|
CILcare specializes in providing drug solutions for hearing and ear disorders. | $42M / Series A / Dec 04, 2024 | |
Avita
|
Avita is a software development company that develops and creates role-playing support avatars using generative AI. | $9.5M / Series A / Aug 23, 2024 | |
Akili Interactive Labs
|
Akili Interactive Labs their broad pipeline of programs to treat cognitive deficiency and improve symptoms associated with medical conditions across neurology and psychiatry, including attention-deficit hyperactivity and disorder (ADHD), major depressive disorder (MDD), autism spectrum disorder (ASD) and various inflammatory diseases. | $110M / Series D / May 26, 2021 | |
Aillis
|
Aillis specializes in the development of testing methods for Influenza using artificial intelligence technology. The company mainly focuses on new methods of diagnosing influenza. The company was founded in 2017. | $184.3M / May 07, 2019 | |
Vast Therapeutics
|
Vast Therapeutics develops inhalable treatments for antibiotic-resistant pathogens present in cystic fibrosis and other respiratory disease patients. The company is in the preclinical stage of developing inhalable therapeutics to treat chronic infections common to the cystic fibrosis population. | $15M / Series A / Jan 15, 2019 | |
PeptiStar
|
PeptiStar is a CDMO (Contract Development and Manufacturing Organization) for peptide APIs, from traditional peptides to constrained peptides including macrocyclic and stapled peptides containing non-natural amino acids. PeptiStar is a technology-based company that provides its customers with high value-added services through its innovativemanufacturing technologies. | $2.8B / Corporate Round / Apr 18, 2018 | |
Peninsula Pharmaceuticals
|
Peninsula Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the licensing, development, and commercialization anti-infective therapies for the treatment of patients with life-threatening infections for the North American and European markets. Peninsula's lead product candidate, doripenem, is a broad-spectrumantibiotic and a new member of the carbapenem class of beta-lactam antibiotics. Peninsula is currently evaluating doripenem in six Phase III clinical trials. In addition, doripenem received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the treatment of nosocomial pneumonia, including ventilator-associated pneumonia (VAP).Peninsula Pharmaceuticals was acquired by Johnson & Johnson, a global manufacturer of health care products, as well as a provider of related services, for the consumer, pharmaceutical, and medical devices and diagnostics markets.Peninsula Pharmaceuticals, Inc. is a privately held biopharmaceutical company focused on developing and commercializing antibiotics to treat life-threatening infections. | $57.9M / Series C / Jan 16, 2004 | |
FunPep
|
FunPep is an Industry-university collaboration bioventure company. | ||
| See all 12 investments → | |||
Co-Investors
Morishita Jintan
2 deals together
Advance Create
1 deal together
Advanced Telecommunications Research Institute
1 deal together
Ajinomoto
1 deal together
Amgen Ventures
1 deal together
A. M. Pappas & Associates
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Shionogi invest in?
Shionogi invests primarily in Biotechnology, Health Care and Medical startups, most often at Series A and Corporate Round stage. Most of the 12 investments tracked by Shizune back companies in Japan. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Shionogi?
Public channels for Shionogi include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Shionogi?
The team at Shionogi includes Jimmy Chen (Senior Director, Pharmaceutical Sciences), Ed Schutter (President and Chief Operating Officer) and Lance Bennett (KAM Leader, West Region). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
